⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
8,673
Total Claims
$4.0M
Drug Cost
827
Beneficiaries
$4,853
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+23%
Cost per patient vs peers
$4,853 vs $3,933 avg
-16%
Brand preference vs peers
43.1% vs 51.2% avg
Brand vs Generic
57% generic
Brand: 3,419 claims · $3.7M
Generic: 4,505 claims · $151K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 283 | $387K |
| Insulin Glargine,hum.Rec.Anlog | 392 | $356K |
| Dulaglutide | 220 | $349K |
| Insulin Lispro | 195 | $314K |
| Insulin Aspart | 182 | $252K |
| Semaglutide | 120 | $229K |
| Dapagliflozin Propanediol | 186 | $221K |
| Sitagliptin Phosphate | 160 | $192K |
| Insulin Lispro | 79 | $105K |
| Insulin Lispro Protamin/Lispro | 61 | $95K |
| Insulin Degludec | 46 | $94K |
| Insulin Aspart Prot/Insuln Asp | 56 | $93K |
| Linagliptin | 89 | $78K |
| Insulin Glargine,hum.Rec.Anlog | 79 | $72K |
| Liraglutide | 33 | $72K |
Prescribing Profile
Patient Profile
71
Avg Age
58%
Female
1.66
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About